Masatoshi Kudo Selected Research

Immunoglobulin G4-Related Disease

12/2022	Disruption of the intestinal barrier exacerbates experimental autoimmune pancreatitis by promoting the translocation of Staphylococcus sciuri into the pancreas.
5/2021	Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease.
2/2021	A unique profile of serum cytokines in type 1 autoimmune pancreatitis and chronic rhinosinusitis.
1/2021	Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease.
1/2021	Intestinal Dysbiosis and Autoimmune Pancreatitis.
1/2020	Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease.
11/2019	Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells.
6/2019	Recent Updates on the Relationship between Cancer and Autoimmune Pancreatitis.
3/2019	Cytokines produced by innate immune cells in IgG4-related disease.
1/2019	The IFN-α-IL-33 Axis as Possible Biomarkers in IgG4-Related Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masatoshi Kudo Research Topics

Disease

443	Hepatocellular Carcinoma (Hepatoma) 05/2024 - 11/2001
196	Neoplasms (Cancer) 02/2024 - 11/2001
58	Liver Neoplasms (Liver Cancer) 05/2024 - 01/2003
32	Neoplasm Metastasis (Metastasis) 07/2022 - 11/2001
29	Fibrosis (Cirrhosis) 12/2022 - 12/2005
27	Inflammation (Inflammations) 04/2024 - 10/2002
27	Infections 12/2022 - 01/2004
25	Liver Diseases (Liver Disease) 12/2022 - 01/2003
25	Chronic Hepatitis C 08/2019 - 01/2002
22	Hypertension (High Blood Pressure) 04/2024 - 10/2013
20	Disease Progression 11/2023 - 01/2011
18	Pancreatic Neoplasms (Pancreatic Cancer) 11/2023 - 01/2006
17	Ulcerative Colitis 03/2024 - 11/2006
16	Autoimmune Pancreatitis 03/2024 - 02/2010
16	Fatigue 08/2023 - 09/2013
16	Immunoglobulin G4-Related Disease 12/2022 - 03/2012
15	Liver Cirrhosis (Hepatic Cirrhosis) 07/2019 - 10/2005
13	Hepatitis C 04/2024 - 12/2006
13	Hepatitis B 04/2024 - 10/2006
13	Hepatitis 01/2023 - 01/2003
12	Pancreatitis 01/2024 - 01/2009
12	Ascites 02/2023 - 02/2006
12	Hemorrhage 01/2023 - 02/2002
11	Chronic Hepatitis B 12/2022 - 01/2011
11	Chronic Hepatitis (Chronic Active Hepatitis) 01/2011 - 01/2002
9	Colitis 03/2024 - 01/2019
9	Thrombosis (Thrombus) 08/2023 - 01/2003
9	Necrosis 04/2022 - 07/2010
9	Carcinogenesis 01/2019 - 01/2011
8	Cholangitis 10/2022 - 01/2011
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2023 - 01/2015
7	Pathologic Constriction (Stenosis) 10/2022 - 11/2016
7	Thrombocytopenia (Thrombopenia) 02/2019 - 12/2010
6	Crohn Disease (Crohn's Disease) 03/2024 - 01/2017
6	COVID-19 03/2024 - 09/2020
6	Adenocarcinoma 11/2023 - 01/2004
6	Non-alcoholic Fatty Liver Disease 08/2023 - 09/2016
6	Diarrhea 06/2023 - 01/2016
6	Ulcer 08/2020 - 09/2009

Drug/Important Bio-Agent (IBA)

109	Sorafenib (BAY 43-9006)FDA Link 12/2023 - 06/2010
57	lenvatinibIBA 04/2024 - 01/2017
46	Bevacizumab (Avastin)FDA Link 05/2024 - 01/2019
45	atezolizumabIBA 05/2024 - 01/2020
43	InterferonsIBA 12/2022 - 01/2002
42	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2016
33	Biomarkers (Surrogate Marker)IBA 08/2023 - 11/2006
25	BilirubinIBA 05/2024 - 02/2006
25	RamucirumabIBA 07/2022 - 07/2015
23	AlbuminsIBA 05/2024 - 01/2011
23	CytokinesIBA 04/2024 - 11/2006
23	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2022 - 12/2006
23	Proteins (Proteins, Gene)FDA Link 07/2022 - 04/2002
21	Immunoglobulin G (IgG)IBA 12/2022 - 02/2010
19	gadolinium ethoxybenzyl DTPA FDA Link 12/2023 - 01/2009
19	SonazoidIBA 01/2021 - 01/2008
19	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 01/2008
16	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2022 - 07/2010
15	Antiviral Agents (Antivirals)IBA 04/2024 - 01/2011
14	pembrolizumabIBA 12/2023 - 01/2017
13	LigandsIBA 11/2023 - 03/2012
13	Contrast MediaIBA 04/2017 - 11/2001
12	acarboxyprothrombin (PIVKA)IBA 04/2024 - 12/2006
12	NivolumabIBA 01/2024 - 01/2017
12	Tumor Biomarkers (Tumor Markers)IBA 10/2019 - 10/2005
11	AntigensIBA 04/2023 - 01/2008
11	Hepatitis B Surface Antigens (HBsAg)FDA Link 12/2021 - 10/2006
11	Interleukin-33IBA 05/2021 - 01/2017
10	Fetal Proteins (Fetoprotein)IBA 05/2024 - 09/2007
10	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2024 - 12/2010
10	NucleotidesIBA 11/2023 - 10/2002
9	Tyrosine Kinase InhibitorsIBA 01/2024 - 01/2011
9	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2011
8	Alanine Transaminase (SGPT)IBA 04/2024 - 01/2008
8	SteroidsIBA 01/2024 - 09/2008
8	entecavir FDA Link 12/2022 - 08/2011
8	GadoliniumIBA 11/2021 - 01/2011
8	Coloring Agents (Dyes)IBA 01/2020 - 12/2002
8	SHU 508 (Levovist)IBA 07/2010 - 11/2001
7	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2023 - 03/2012
7	regorafenibIBA 06/2023 - 01/2016
7	CateninsIBA 04/2023 - 05/2014
7	EnzymesIBA 10/2022 - 10/2011
7	Serum AlbuminIBA 08/2021 - 02/2006
7	RNA (Ribonucleic Acid)IBA 01/2017 - 01/2002
6	Prednisolone (Predate)FDA LinkGeneric 04/2024 - 07/2020
6	tremelimumabIBA 12/2023 - 01/2021
6	durvalumabIBA 12/2023 - 01/2021
6	cabozantinibIBA 06/2023 - 05/2018
6	Pentetic Acid (DTPA)FDA LinkGeneric 01/2017 - 04/2011

Therapy/Procedure

228	Therapeutics 05/2024 - 01/2002
66	Radiofrequency Ablation 10/2023 - 01/2003
31	Drug Therapy (Chemotherapy) 04/2024 - 01/2009
28	Immunotherapy 02/2024 - 03/2018
17	Stents 09/2023 - 01/2011
13	Aftercare (After-Treatment) 10/2022 - 03/2003
12	Hepatectomy 10/2023 - 03/2002
11	Molecular Targeted Therapy 09/2019 - 01/2008
9	Microbubbles 05/2010 - 11/2001
8	Surgical Instruments (Clip) 06/2021 - 01/2003
6	Electrodes (Electrode) 10/2016 - 07/2004